359 related articles for article (PubMed ID: 18302761)
1. NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
Bratasz A; Selvendiran K; Wasowicz T; Bobko A; Khramtsov VV; Ignarro LJ; Kuppusamy P
J Transl Med; 2008 Feb; 6():9. PubMed ID: 18302761
[TBL] [Abstract][Full Text] [Related]
2. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.
Selvendiran K; Bratasz A; Tong L; Ignarro LJ; Kuppusamy P
Cell Cycle; 2008 Jan; 7(1):81-8. PubMed ID: 18196976
[TBL] [Abstract][Full Text] [Related]
3. Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin.
Bratasz A; Weir NM; Parinandi NL; Zweier JL; Sridhar R; Ignarro LJ; Kuppusamy P
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3914-9. PubMed ID: 16497833
[TBL] [Abstract][Full Text] [Related]
4. Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6.
Li S; Yi Z; Li M; Zhu Z
J Ovarian Res; 2023 Nov; 16(1):212. PubMed ID: 37940982
[TBL] [Abstract][Full Text] [Related]
5. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
Tang XH; Li M; Deng S; Lu MS
Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
[TBL] [Abstract][Full Text] [Related]
6. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
7. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
Rose WC; Basler GA
In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379
[TBL] [Abstract][Full Text] [Related]
8. The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.
Mueller T; Pfankuchen DB; Wantoch von Rekowski K; Schlesinger M; Reipsch F; Bendas G
Molecules; 2017 May; 22(5):. PubMed ID: 28467373
[TBL] [Abstract][Full Text] [Related]
9. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
[TBL] [Abstract][Full Text] [Related]
10. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
[TBL] [Abstract][Full Text] [Related]
11. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts.
Leonetti C; Scarsella M; Zupi G; Zoli W; Amadori D; Medri L; Fabbri F; Rosetti M; Ulivi P; Cecconetto L; Bolla M; Tesei A
Mol Cancer Ther; 2006 Apr; 5(4):919-26. PubMed ID: 16648562
[TBL] [Abstract][Full Text] [Related]
13. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
15. Chloroquine reverses chemoresistance via upregulation of p21
Hwang JR; Kim WY; Cho YJ; Ryu JY; Choi JJ; Jeong SY; Kim MS; Kim JH; Paik ES; Lee YY; Han HD; Lee JW
Cell Death Dis; 2020 Dec; 11(12):1034. PubMed ID: 33277461
[TBL] [Abstract][Full Text] [Related]
16. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
17. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
18. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
Song K; Li Z; Seth P; Cowan KH; Sinha BK
Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
[TBL] [Abstract][Full Text] [Related]
20. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]